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melanogenesis, gametogenesis, and reg-
ulation of gastric slow waves in addition 
to mast cell growth. Thus, Kit-deficient 
mice not only lack cutaneous mast cells 
but also display macrocytic anemia, 
loss of hair pigmentation, sterility, and 
reduced numbers of gastrointestinal 
pacemaker cells. In humans, KIT loss-of-
function mutations result in piebaldism, 
an autosomal dominant disorder of pig-
mentation characterized by patches of 
white skin and hair. In contrast, KIT gain-
of-function mutations are associated with 
gastrointestinal stromal cell tumors and 
other cancers. Small compounds, such 
as imatinib mesylate, that can suppress 
KIT tyrosine kinase activity, have been 
shown to be clinically useful in treating 
these tumors.
The c-KIT codon 816 mutation that 
has been associated with mastocytosis 
was first identified in the HMC-1 human 
mast cell line, established from a patient 
with mast cell leukemia (Furitsu et al., 
1993). Nagata et al. (1995) subsequent-
ly reported a point mutation causing a 
D816V substitution in the kinase domain 
of KIT in the peripheral blood of masto-
cytosis patients with myeloid dysplasia. 
The same mutation was identified in both 
skin and spleen from a patient with urti-
caria pigmentosa and aggressive system-
ic mastocytosis, establishing mastocytosis 
as a neoplastic process (Longley et al., 
1996). It is now accepted that mast cells 
of the majority of adult patients carry 
point mutations in c-KIT, leading to SCF-
independent autophosphorylation of the 
receptor and autonomous cell growth.
In contrast to adult cases, which are 
persistent or progressive, mastocytosis 
is often transient and limited in children 
(Hartmann and Henz, 2001). Notably, 
most pediatric patients lack c-KIT codon 
816 mutations, and the mechanism 
causing mast cell proliferation in these 
pediatric patients has been unclear. In 
this issue, Bodemer et al. report a multi-
center study of 50 pediatric patients with 
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Adult mastocytosis is usually persistent and caused by c-KIT codon 816–activating 
mutations. Pediatric mastocytosis is often transient, and the molecular mechanism 
driving mast cell proliferation in pediatric cases remains unclear. In this issue, 
Bodemer et al. report novel c-KIT mutations in a large percentage of pediatric 
cases, identifying both similarities and fundamental differences in the mechanisms 
causing adult and pediatric mastocytosis.
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The molecular mechanism of childhood 
mastocytosis has been veiled in mystery. 
In this issue, Bodemer et al. analyze the 
entire sequence of c-KIT in cutaneous 
biopsy specimens from pediatric patients 
with mastocytosis and identify a group of 
oncogenic somatic c-KIT mutations that 
activate the KIT tyrosine kinase, similar 
to the mutations found in adults.
Mastocytosis comprises a range of 
heterogeneous disorders associated 
with abnormal proliferation of mast 
cells (Metcalfe, 2008). Its clinical fea-
tures were first reported by Nettleship 
and Tay (1869) 8 years before Ehrlich 
(1878) described tissue cells with dense 
metachromatic granules that turned from 
blue to pinkish-purple with the aniline 
dyes, which he called mastzellen (mast 
cells). Cutaneous mastocytosis is charac-
terized by macules, papules, nodules, or 
diffuse infiltration of the skin, often asso-
ciated with localized hyperpigmentation 
(Figure 1). Gentle rubbing of the lesions 
induces histamine release from mechan-
ically activated mast cells, causing local 
wheals, erythema, and often pruritus, a 
phenomenon termed “Darier’s sign.”
By grafting bone marrow cells into 
irradiated mice, Kitamura et al. (1977) 
discovered that mast cells originate 
from bone marrow. Multipotential 
progenitor cells capable of becoming 
mast cells leave the bone marrow and 
enter the circulation, but they complete 
their differentiation only after arriving 
in peripheral tissues such as the lung, 
bowel, and skin and coming under the 
influence of local stromal cells. IL-3 is 
critical for the growth and survival of 
murine mast cells, but Saito et al. (1988) 
reported that IL-3 alone was not suffi-
cient. The critical mast cell growth factor 
in humans has now been identified to 
be stem cell factor (SCF), which induces 
proliferation of human mast cells while 
they retain their characteristic phenotype 
and function (Kambe et al., 2001).
The receptor for SCF is KIT (CD117), 
a 145-kDa protein with an extracel-
lular domain consisting of five Ig-like 
domains, a transmembrane region, a jux-
tamembrane intracellular domain, and a 
tyrosine kinase domain (Figure 2). KIT is 
a type III transmembrane tyrosine kinase 
that is encoded by the human homolog of 
the proto-oncogene KIT, which is locat-
ed on chromosome 4q12. SCF exists as 
a homodimer, and binding to the Ig-like 
extracellular domains of two KIT mol-
ecules induces homodimerization of KIT 
and autophosphorylation at tyrosine resi-
dues on their cytosolic tails, leading to a 
cascade of signals that cause activation 
of transcription factors necessary for cell 
growth. KIT is expressed on hematopoi-
etic progenitors, melanocytes, germ 
cells, and the interstitial cells of Cajal 
as well as mast cells. KIT–SCF signaling 
is required for normal hematopoiesis, 
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In contrast to adults, 
mastocytosis is often 
transient and limited 
in children.
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of tyrosine or isoleucine in codon 816), 
similar to the 36% of pediatric cases 
with codon 816 mutations reported by 
Longley et al. (1999). Most importantly, 
Bodemer et al. identified mutations locat-
ed outside exon 17 in 44% of pediatric 
cases, and most of these were located 
in the fifth Ig-like domain encoded by 
exons 8 and 9. All the mutations identi-
fied caused constitutive activation of KIT.
mastocytosis. By analyzing the entire 
c-KIT coding sequence in cutaneous 
biopsy specimens, they found that most 
pediatric cases, like most adult cases, 
were associated with KIT-activating 
somatic mutations. In their study, 42% of 
pediatric cases had mutations in codon 
816 affecting the kinase domain (18 
of 50 children had D816V mutations 
and 3 other children had substitutions 
The observation that mast cells in the 
skin lesions of pediatric mastocytosis 
patients contain KIT-activating mutations 
is novel and critical for understanding 
the pathophysiological mechanism of 
mastocytosis, although an important 
question remains to be answered: if 
mast cell proliferation depends on KIT 
gain-of-function mutations in both pedi-
atric and adult mastocytosis, why does 
the pediatric form, but not the adult 
form, exhibit spontaneous regression? 
Long-term follow-up is needed to deter-
mine whether spontaneous resolution 
is associated with specific mutations. 
Differential analysis comparing down-
stream signaling cascades caused by 
auto phosphorylation of KIT in pediatric 
and adult cases of mastocytosis may 
provide insight into this question, and 
understanding how these signaling path-
ways differ may open new avenues for 
treating mastocytosis as well as other 
cancers associated with KIT-activating 
mutations that do not respond to 
currently available KIT inhibitors.
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caused constitutive activation of KIT, leading to mast cell growth. The numbers of identical mutations 
reported by Bodemer et al. (2010) are indicated in parentheses. SCF, stem cell factor.
Figure 1. Pediatric mastocytosis (urticaria pigmentosa). Gentle rubbing of the lesion induces local 
wheals and erythema, termed Darier’s sign.
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It Is Better to Flush than  
to Break under Pressure
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In this issue Fromy et al. describe alterations in pressure-induced vasodilation 
in the populations most prone to development of pressure ulcers of the 
skin. Advancing our understanding regarding the basic pathophysiological 
mechanisms mediating the development of pressure ulcers will allow for 
better delineation of populations at risk. This study provides novel insights into 
this important and poorly understood entity, using tools that are potentially 
deployable into clinical practice.
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Pressure ulcers are a common and cost-
ly problem. The estimated incidence of 
pressure ulcers ranges from 0.4 to 38% 
in general acute care (hospitals), from 
2.2 to 23.9% in long-term care, and 
from 0 to 17% in home care (Cuddigan 
et al., 2001). The financial impact of 
pressure ulcers is substantial. The esti-
mated cost of healing a single pressure 
ulcer approaches $40,000 and rises if 
litigation costs are factored in (Lyder, 
2003; Voss et al., 2005).
Since the late 1950s, when the role 
of ischemia in pressure ulcer develop-
ment was first reported (Kosiak, 1959), 
elucidation of the pathophysiology of 
pressure ulcers and their treatment has 
advanced slowly. More than 100 risk 
factors for pressure ulcers have been 
described, supporting a multifactorial 
etiology. Prediction tools based on this 
broad range of risk factors have been 
employed to identify specific at-risk 
populations and to reduce the inci-
dence of pressure ulcers. However, 
these tools tend to overestimate risk, 
owing to the breadth of clinical cat-
egories used to identify at-risk patients, 
resulting in misdirected and wasted 
resources.
Significant study has further char-
acterized the pathogenesis of pressure 
ulcers based on a on a micro vascular 
target. Such fundamental work is 
essential to focus prediction tools on 
specific high-risk populations and 
scenarios and to improve ulcer clas-
sifications and tissue-injury models. 
Understanding the underlying processes 
in pressure ulcer development may ulti-
mately facilitate their prevention and 
treatment.
In this issue, Fromy et al. describe an 
elegant in vivo human model used to 
demonstrate the physiologic correlates 
of known epidemiologic risk factors for 
pressure ulcer development. Previous 
work by these authors identified a 
vasodilatory axon reflex response 
to nonnoxious pressure stimulation 
mediated by capsaicin-sensitive nerve 
terminals in human skin (pressure-
induced vasodilatation) (Fromy et al., 
1998). This pathway appears to func-
tion as a tissue-protective mechanism, 
increasing local blood flow to the skin 
in response to external pressure and 
delaying the deleterious effects of pres-
sure by preventing ischemia. Further 
work in animal models established 
the presence of this reflex in rats and 
revealed that local pressure stimulates 
the release of calcitonin gene-related 
peptide (a sensory neuropeptide) 
and neuronal nitric oxide by primary 
afferent nerves. These mediators then 
stimulate the release of endothelial 
nitric oxide, resulting in vascular 
smooth muscle relaxation. Later studies 
by Fromy et al. (2007) demonstrated 
a neuroendocrine-mediated loss of 
pressure-induced vasodilatation in 
rats subjected to acute pain. These 
physiologic experiments identified pain 
as an additional risk factor for pressure 
ulcers.
In their article in this issue, Fromy 
et al. report altered microcirculation 
in response to pressure in both neuro-
pathic and nonneuropathic older sub-
jects (60–75 years old) as compared 
with younger subjects (20–35 years 
old). Younger subjects demonstrated 
robust vasodilation after application 
of local pressure. Older subjects with-
out neuro pathy exhibited a markedly 
lower pressure-induced vaso dilatory 
response as compared with younger 
subjects. Furthermore, neuropathic 
older subjects lacked any pressure-
induced vaso dilatory response, 
demonstrating a decrease in cutane-
ous vascular conductance after pres-
sure application (Fromy et al., 2010). 
These findings provide a mechanism 
with which to explain the physi-
ologic decline of vascular responses 
with age and sensory deficits, result-
ing in a decreased ability to protect 
the skin from pressure-induced isch-
emia. The work provides direct in 
vivo physiologic data to support aging 
and neuro pathy as risk factors for the 
development of pressure ulcers. It also 
provides a useful framework in which 
to consider how advancing age and 
loss of neurologic function may alter 
vascular function in organs other than 
